NU SKIN ENTERPRISES, INC. - 10-Q Summary (Q2 2025)
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Nu Skin Enterprises, Inc. is a holding company developing and distributing premium beauty and wellness products under the Nu Skin, Pharmanex, and ageLOC brands. The company operates through nine segments: seven geographic Nu Skin regions and two Rhyz segments (Manufacturing and Rhyz Other).
Key Financial Metrics
| Metric | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Revenue | $386.1 million | $439.1 million | $750.6 million | $856.4 million |
| Gross Profit | $265.7 million | $307.2 million | $512.7 million | $601.2 million |
| Gross Margin | 68.8% | 70.0% | 68.3% | 70.2% |
| Operating Income | $30.8 million | ($125.6 million) | $20.9 million | ($116.7 million) |
| Net Income | $21.1 million | ($118.3 million) | $128.6 million | ($118.8 million) |
| Diluted EPS | $0.43 | ($2.38) | $2.59 | ($2.39) |
| Cash from Operations (YTD) | $36.2 million | $54.5 million | N/A | |
| Free Cash Flow (YTD) | $22.6 million | $34.1 million | ||
| Total Debt (Outstanding) | $250.0 million | $395.0 million | N/A | |
| Cash & Equivalents | $264.2 million | $224.3 million |
Note: Debt figures reflect the sum of term loan ($235.0M) and revolving credit facility ($15.0M) balances as of June 30, 2025.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 12% year-over-year (Q2) and 12% (YTD), driven by macroeconomic challenges, reduced consumer spending, and declines in Customers (-14%), Paid Affiliates (-16%), and Sales Leaders (-23%).
- Profitability Turnaround: The company returned to profitability in Q2 2025 ($21.1M net income) compared to a significant loss in Q2 2024 ($118.3M). This improvement is largely due to the absence of the $149.4M restructuring and impairment charges recorded in Q2 2024.
- Asset Sale Impact: The sale of the Mavely entity in Q1 2025 generated a pre-tax gain of $176.2 million, significantly boosting YTD net income. Net proceeds were approximately $193.7 million.
- Debt Reduction: Total debt decreased by approximately $145 million in the first half of 2025, utilizing proceeds from the Mavely sale to pay down the term loan and revolving credit facility.
- Impairments: A $25.1 million impairment charge was recorded in Q1 2025 for the BeautyBio asset group due to a strategic shift and reduced revenue forecasts. Additionally, a $28.1 million non-cash loss was recorded on an equity investment.
Guidance, Outlook, and Risks
- Strategic Priorities: Focus remains on business model optimization, rollout of sales performance plan enhancements, and expansion into India (formal launch expected mid-2026). A limited preview of the Prysm iO device is underway, but material revenue is not expected in 2025.
- Tariff Risks: Management estimates up to $5 million in incremental cost pressure for the remainder of 2025 due to tariffs, though the impact has been minimal so far.
- Interest Rate Exposure: Interest rate swaps maturing July 31, 2025, will result in an increase in the effective interest rate upon maturity.
- Regulatory Environment: The company is assessing the impact of the newly enacted "One Big Beautiful Bill Act" (OBBBA) on its tax provisions.
- Market Headwinds: Continued softness in key markets including Mainland China, South Korea, and Europe/Africa due to inflation and political instability.
Investor Verification Checklist
- Mavely Sale Proceeds: Verify the finalization of net working capital adjustments and the receipt of the remaining $1.7 million expected in Q3 2025.
- BeautyBio Strategy: Monitor the execution of the strategic shift for the BeautyBio asset group and its impact on future impairment risks or revenue recovery.
- Debt Covenant Compliance: Confirm continued compliance with the Credit Agreement leverage ratio (max 2.75:1) and interest coverage ratio (min 3.00:1) following the debt paydown.
- India Market Launch: Track progress toward the mid-2026 formal launch in India and associated capital requirements.
- Tariff Impact: Assess the realization of the estimated $5 million incremental cost pressure from tariffs in the second half of 2025.